Abstract
In this issue,1 Singh et al. report on the effects of the angiotensin 1 receptor blocker telmisartan in reducing abdominal aortic aneurysm (AAA) peak wall stress (PWS) and the peak wall rupture index (PWRI) in a subgroup of patients with small AAAs from the Telmisartan in the Management of Abdominal Aortic Aneurysm (TEDY) trial. In this randomised study, no effects upon AAA growth with telmisartan were demonstrated in spite of mechanisms linked to vascular protection associated with telmisartan, for example improvement of arterial remodelling, anti-oxidation, and antifibrotic effects in an animal model.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Vascular and Endovascular Surgery
Paper Title
Journal
Date
